JPWO2019238882A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019238882A5 JPWO2019238882A5 JP2020568955A JP2020568955A JPWO2019238882A5 JP WO2019238882 A5 JPWO2019238882 A5 JP WO2019238882A5 JP 2020568955 A JP2020568955 A JP 2020568955A JP 2020568955 A JP2020568955 A JP 2020568955A JP WO2019238882 A5 JPWO2019238882 A5 JP WO2019238882A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antigen
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 48
- 239000000427 antigen Substances 0.000 claims 32
- 102000038129 antigens Human genes 0.000 claims 32
- 108091007172 antigens Proteins 0.000 claims 32
- 102000003815 Interleukin-11 Human genes 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 230000002440 hepatic Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 102000004553 Interleukin-11 Receptors Human genes 0.000 claims 1
- 108010017521 Interleukin-11 Receptors Proteins 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076402A JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1809699.0 | 2018-06-13 | ||
| GBGB1809699.0A GB201809699D0 (en) | 2018-06-13 | 2018-06-13 | IL-11 antibodies |
| PCT/EP2019/065598 WO2019238882A1 (en) | 2018-06-13 | 2019-06-13 | Il-11 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076402A Division JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535733A JP2021535733A (ja) | 2021-12-23 |
| JPWO2019238882A5 true JPWO2019238882A5 (zh) | 2022-06-20 |
Family
ID=63042160
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568955A Pending JP2021535733A (ja) | 2018-06-13 | 2019-06-13 | Ｉｌ−１１抗体 |
| JP2024076402A Pending JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076402A Pending JP2024105466A (ja) | 2018-06-13 | 2024-05-09 | Ｉｌ－１１抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11084874B2 (zh) |
| EP (1) | EP3807314A1 (zh) |
| JP (2) | JP2021535733A (zh) |
| KR (1) | KR20210031690A (zh) |
| CN (1) | CN113056481A (zh) |
| AU (1) | AU2019286795A1 (zh) |
| BR (1) | BR112020025443A2 (zh) |
| CA (1) | CA3102483A1 (zh) |
| CL (1) | CL2020003223A1 (zh) |
| CO (1) | CO2020015383A2 (zh) |
| CR (1) | CR20210009A (zh) |
| DO (1) | DOP2020000245A (zh) |
| EA (1) | EA202092668A1 (zh) |
| EC (1) | ECSP21000695A (zh) |
| GB (1) | GB201809699D0 (zh) |
| IL (1) | IL279356A (zh) |
| JO (1) | JOP20200309A1 (zh) |
| MA (1) | MA52884A (zh) |
| MX (1) | MX2020013583A (zh) |
| PE (1) | PE20211498A1 (zh) |
| PH (1) | PH12020552232A1 (zh) |
| SA (1) | SA520420801B1 (zh) |
| SG (1) | SG11202011782XA (zh) |
| TW (1) | TW202003560A (zh) |
| WO (1) | WO2019238882A1 (zh) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| WO2018109174A2 (en) | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| CA3126322A1 (en) | 2019-01-21 | 2020-07-30 | Singapore Health Services Pte. Ltd. | Treatment of hepatotoxicity |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| MX2021013356A (es) | 2019-05-03 | 2022-03-11 | Singapore Health Serv Pte Ltd | Tratamiento y prevencion de enfermedades metabolicas. |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| US20230235029A1 (en) * | 2020-07-20 | 2023-07-27 | Integrated Biotherapeutics, Inc. | Broadly neutralizing binding molecules against marburgviruses |
| CN113651888B (zh) * | 2020-08-13 | 2022-08-16 | 广东东阳光药业有限公司 | Il-11的抗体及其应用 |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| CN113980129B (zh) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | 一组il-11单克隆抗体及其医药用途 |
| CN117157317A (zh) | 2021-02-26 | 2023-12-01 | 拜耳公司 | 用于治疗异常子宫出血的IL-11或IL-11Ra的抑制剂 |
| EP4376948A1 (en) | 2021-07-26 | 2024-06-05 | Boehringer Ingelheim International GmbH | Treatment and prevention of alcoholic liver disease |
| EP4386002A1 (en) * | 2021-08-12 | 2024-06-19 | Sunshine Lake Pharma Co., Ltd. | Il-11 humanized antibody and application thereof |
| WO2023111196A1 (en) | 2021-12-16 | 2023-06-22 | Singapore Health Services Pte. Ltd. | Treatment and prevention of glomerular disease |
| CN116891528A (zh) * | 2022-01-29 | 2023-10-17 | 迈威(上海)生物科技股份有限公司 | 一种抗白介素-11的抗体及其应用 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI335336B (zh) * | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| US8518888B2 (en) * | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| WO2018109174A2 (en) * | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| RU2016151730A (ru) | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
-
2018
- 2018-06-13 GB GBGB1809699.0A patent/GB201809699D0/en not_active Ceased
-
2019
- 2019-06-13 TW TW108120516A patent/TW202003560A/zh unknown
- 2019-06-13 SG SG11202011782XA patent/SG11202011782XA/en unknown
- 2019-06-13 KR KR1020217000825A patent/KR20210031690A/ko unknown
- 2019-06-13 MX MX2020013583A patent/MX2020013583A/es unknown
- 2019-06-13 BR BR112020025443-6A patent/BR112020025443A2/pt unknown
- 2019-06-13 PE PE2020001992A patent/PE20211498A1/es unknown
- 2019-06-13 WO PCT/EP2019/065598 patent/WO2019238882A1/en active Application Filing
- 2019-06-13 EP EP19734285.0A patent/EP3807314A1/en active Pending
- 2019-06-13 CR CR20210009A patent/CR20210009A/es unknown
- 2019-06-13 US US16/440,840 patent/US11084874B2/en active Active
- 2019-06-13 EA EA202092668A patent/EA202092668A1/ru unknown
- 2019-06-13 MA MA052884A patent/MA52884A/fr unknown
- 2019-06-13 CA CA3102483A patent/CA3102483A1/en active Pending
- 2019-06-13 CN CN201980054506.1A patent/CN113056481A/zh active Pending
- 2019-06-13 JO JOP/2020/0309A patent/JOP20200309A1/ar unknown
- 2019-06-13 JP JP2020568955A patent/JP2021535733A/ja active Pending
- 2019-06-13 AU AU2019286795A patent/AU2019286795A1/en active Pending
-
2020
- 2020-12-09 CO CONC2020/0015383A patent/CO2020015383A2/es unknown
- 2020-12-10 IL IL279356A patent/IL279356A/en unknown
- 2020-12-11 CL CL2020003223A patent/CL2020003223A1/es unknown
- 2020-12-11 DO DO2020000245A patent/DOP2020000245A/es unknown
- 2020-12-13 PH PH12020552232A patent/PH12020552232A1/en unknown
- 2020-12-13 SA SA520420801A patent/SA520420801B1/ar unknown
-
2021
- 2021-01-06 EC ECSENADI2021695A patent/ECSP21000695A/es unknown
- 2021-03-25 US US17/212,456 patent/US20210230266A1/en active Pending
-
2024
- 2024-03-01 US US18/592,665 patent/US20240190953A1/en active Pending
- 2024-03-01 US US18/592,746 patent/US20240270837A1/en active Pending
- 2024-05-09 JP JP2024076402A patent/JP2024105466A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019238882A5 (zh) | ||
| JP7140743B2 (ja) | Ｆｃ結合能を有する融合タンパク質を含む細胞外小胞の使用 | |
| HRP20191824T1 (hr) | Agonistička sredstva za vezivanje tnf receptora | |
| JP7328217B2 (ja) | 操作された細胞外小胞の親和性精製 | |
| JP2023527927A (ja) | 新型コロナウイルス（ｓａｒｓ－ｃｏｖ－２）スパイクタンパク質結合分子及びその使用 | |
| Rosin et al. | Regulation and role of connective tissue growth factor in AngII-induced myocardial fibrosis | |
| JP2022061992A5 (zh) | ||
| JP2019521140A (ja) | 結合タンパク質−小分子コンジュゲートのｅｖ媒介送達 | |
| JP2017029157A5 (zh) | ||
| JP2017511130A5 (zh) | ||
| CN103119063B8 (zh) | 结合至血管内皮生长因子2（vegfr-2/kdr）上并阻断其活性的重组抗体结构 | |
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| JP2012501670A5 (zh) | ||
| JP2010511388A5 (zh) | ||
| JP2011207882A5 (zh) | ||
| JPWO2020016662A5 (zh) | ||
| JP2009529915A5 (zh) | ||
| JP2019530440A (ja) | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 | |
| JP2012524524A5 (zh) | ||
| JP6979698B2 (ja) | ヒト化抗−ｂａｇ３抗体 | |
| CA3145291A1 (en) | Methods for treating ran protein-associated neurological diseases | |
| WO2022061594A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| Verma et al. | Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy | |
| JP2014515600A5 (zh) | ||
| CN111629752A (zh) | 用于预防或治疗细胞迁移相关疾病的含作为有效成分的与赖氨酰-tRNA合成酶N-末端特异性结合的抗体的药物组合物 |